Multiple Sclerosis
Multiple Sclerosis
Also known as:MS, disseminated sclerosis
Multiple sclerosis is a chronic autoimmune demyelinating disease of the central nervous system in which the immune system mistakenly attacks the myelin sheath covering nerve fibers, disrupting nerve signal transmission and causing recurrent episodes of neurological dysfunction.
Start Here
A quick guide to the next step: which department to start with, what to prepare, and what to ask.
Neurology, preferably a neuroimmunology specialist. Seek prompt evaluation for acute vision loss, limb weakness, sensory disturbances, or bladder/bowel dysfunction.
This is a chronic inflammatory autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath, disrupting nerve conduction. The disease course is typically relapsing-remitting, with some patients later converting to secondary progressive disease.
There is currently no cure, but multiple disease-modifying therapies (DMTs) can significantly reduce relapses and slow disability progression. High-dose corticosteroids are used for acute relapses. Early treatment is critical for prognosis.
Not a traditional single-gene inherited disease, but there is some genetic susceptibility (especially HLA-DRB1*15:01). First-degree relatives have a slightly elevated risk compared to the general population. Environmental factors such as vitamin D deficiency and EB virus infection also play important roles.
Early symptoms (blurred vision, limb numbness, dizziness) mistaken for cervical spondylosis, eye strain, or anxiety; after the first episode symptoms resolve spontaneously, so patients neglect follow-up; primary care hospitals lack MRI and cerebrospinal fluid testing capabilities.
Common Search and Care Questions
This page helps patients and families organize care leads. It does not replace a clinician’s diagnosis or treatment plan. For testing, medication, referrals, emergency care, and support applications, follow qualified clinicians, medical institutions, support organizations, and official sources.
Diagnosis Path
Organized around the practical patient journey: identify clues, avoid common delays, then prepare for care.
When to Suspect It
- Young adult develops acute monocular vision loss (optic neuritis) or blurred vision in both eyes.
- Limb numbness, weakness, or tingling, especially unilateral, lasting more than 24 hours.
- Gait instability, ataxia, or vertigo that does not resolve after excluding ENT causes.
- Urinary difficulty, urinary retention, or incontinence accompanied by lower limb sensory abnormalities.
- Symptoms peak within days, persist for weeks, then partially or completely resolve, suggesting a relapsing-remitting course.
Common Wrong Turns
- Optic neuritis treated as a common eye disease without brain MRI to rule out MS.
- Limb numbness and weakness misdiagnosed as cervical spondylosis, lumbar disease, or cerebral blood supply insufficiency.
- Dizziness treated as benign paroxysmal positional vertigo or Meniere disease without comprehensive neurological evaluation.
- After the first episode symptoms resolve, the patient discontinues medication or misses follow-up.
- Delay in starting disease-modifying therapy (DMT), missing the early treatment window.
Departments to Start With
- Neurology (neuroimmunology specialty)
- Ophthalmology (when optic neuritis is the first symptom)
- Physical Medicine and Rehabilitation (during functional recovery)
- Urology (when voiding dysfunction is severe)
Before the Visit
- Document the timing, symptoms, duration, and recovery of each episode in detail.
- Bring all prior brain and spinal cord MRI films and reports.
- If lumbar puncture/oligoclonal band testing was done, bring those results.
- List all prior medication history and allergies.
- Ask the physician whether the 2017 McDonald criteria are met.
Tests to Ask About
- Brain and spinal cord MRI with and without contrast (to demonstrate dissemination in time and space).
- Cerebrospinal fluid analysis (oligoclonal bands, IgG index).
- Visual evoked potentials (VEP, to assess optic nerve conduction).
- Serum AQP4-IgG and MOG-IgG (to exclude neuromyelitis optica spectrum disorder).
- Serum vitamin D level.
- Routine blood tests (to exclude infection, autoimmune disease, etc.).
Questions for the Doctor
- What type of MS do I have — relapsing-remitting or progressive?
- What disease-modifying therapies are suitable for me? What are their efficacy, side effects, and costs?
- How do we assess response to steroid treatment? When can DMT be started?
- Do I need to stop medication during pregnancy? Which drugs are relatively safe?
- What should I pay attention to in daily life? Any restrictions on exercise, diet, or vaccination?
Basic Information
Medical Notes
More complete medical explanations are kept here for discussion with clinicians.
Symptoms
MS symptoms vary depending on lesion location and commonly include: optic neuritis (acute monocular vision loss, eye pain), limb weakness or numbness, sensory disturbances (pins and needles, burning), ataxia, vertigo, fatigue, bladder and bowel dysfunction, cognitive decline, and mood disorders (depression, anxiety).
The typical course is relapsing-remitting (RRMS), with acute attacks followed by partial or complete recovery. Approximately 50% of RRMS patients convert to secondary progressive MS (SPMS) after 10-20 years, with gradually accumulating disability. About 10-15% of patients have primary progressive MS (PPMS), with continuous progression from onset.
Diagnosis
Diagnosis is based on the 2017 revised McDonald criteria, with core requirements demonstrating dissemination in time and space of CNS lesions. This requires integration of clinical presentation, MRI (brain and spinal cord), cerebrospinal fluid examination, and evoked potentials.
MRI is a key diagnostic and monitoring tool: typical lesions are located in the periventricular, juxtacortical, infratentorial (brainstem/cerebellum), and spinal cord regions. Cerebrospinal fluid oligoclonal bands support the diagnosis. Differential diagnosis includes neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease, acute disseminated encephalomyelitis (ADEM), and cerebrovascular disease.
Treatment
Acute relapses: high-dose methylprednisolone intravenous pulse (typically 500-1000 mg/day for 3-5 days), with plasma exchange if needed.
Disease-modifying therapy (DMT) is the cornerstone of MS management. First-line agents include interferon beta, glatiramer acetate, teriflunomide, fingolimod, and dimethyl fumarate; high-efficacy agents include natalizumab, alemtuzumab, ocrelizumab, and cladribine. Drug selection should consider disease activity, safety profile, patient preferences, and accessibility.
Symptomatic treatment includes: antispasticity medications, bladder dysfunction medications, fatigue management, pain control, cognitive rehabilitation, and psychological support.
Long-term Care
Long-term follow-up includes: periodic MRI to assess disease activity, EDSS disability scoring, cognitive function screening, mood assessment, and quality-of-life evaluation. Monitor DMT safety (infection risk, liver function, blood counts, cardiac function, etc.).
Lifestyle management: moderate exercise (swimming, yoga, etc.) helps maintain function; smoking cessation (smoking increases disease activity); maintaining adequate vitamin D levels; avoiding excessive heat exposure (heat can temporarily worsen symptoms); regular sleep schedule and fatigue management. Vaccinations should be completed before starting immunosuppressants; live vaccines should be avoided during immunosuppression.
Fertility and Family
MS itself does not affect fertility, but some DMTs may affect the fetus (e.g., teriflunomide has teratogenic risk and requires drug elimination before conception). Relapse risk may decrease during pregnancy but increases 3-6 months postpartum.
Some medications can be used safely during pregnancy and lactation (e.g., interferon beta, glatiramer acetate). Women planning pregnancy should consult their neurologist to adjust medications. MS is not a single-gene inherited disease, but offspring have a slightly elevated risk (approximately 2-5%).
When to Seek Urgent Care
Seek immediate care for: acute severe vision loss, new severe limb weakness or paralysis, acute urinary retention, severe swallowing difficulty with choking, seizures, or altered consciousness with high fever. Avoid self-administering immune-enhancing supplements or folk remedies during relapses.
Prognosis
Early DMT significantly improves prognosis. Most RRMS patients can maintain functional independence for a long time, but some eventually progress to SPMS.